CORE2 CS6 – TIMI 72b

CORE2 CS6 – TIMI 72b is a phase 3 multicenter, randomized, double-blind, placebo-controlled trial in ~390 patients to evaluate the safety and efficacy of olezarsen, an antisense oligonucleotide inhibitor of apoC-III production, administered subcutaneously to patients with severe hypertriglyceridemia.

CS6

CORE2 CS6 on ClinicalTrials.gov

CONTACT US about CORE2 CS6

%d bloggers like this:
search previous next tag category expand menu location phone mail time cart zoom edit close